Catalog Technologies, which is based at the Harvard Life Lab, emerges from stealth with $9M in funding to help commercialize its DNA-based data storage method
The practice of encoding data in DNA molecules could be inching closer to graduating from research labs to finding practical commercial use.
Context & Ripple Effects
DNA-based storage has been circling commercialization since Microsoft bought 10M strands of synthetic DNA from Twist Bioscience in 2016 to test long-term archiving — a signal that hyperscale buyers saw density advantages worth probing. Catalog Technologies, incubated at the Harvard Life Lab, is now the first named startup in this coverage to take the method out of stealth and put venture capital behind it.
The $9M round reads as an early bet in what became a sustained funding arc: Catalog went on to raise a $35M Series B in 2021, while adjacent genomic-data infrastructure players like DNAnexus pulled in nine-figure rounds over the same period. The throughline is investors treating biological molecules as a storage and computing substrate, not just a research subject.
First-order effects
- Catalog gains the capital to move its DNA encoding method from lab demonstration toward a commercial product, with the Harvard Life Lab as its operating base.
Second-order effects
- Synthetic DNA suppliers become the upstream dependency: if Catalog scales, demand for custom strands follows the path Microsoft already blazed with Twist Bioscience.
Third-order effects
- If the funding pattern holds — Catalog's later $35M round suggests it did — DNA storage consolidates into a startup-led category competing for archival workloads where density and longevity outweigh write-speed limits.
The trend: DNA-based data storage is shifting from corporate research experiments like Microsoft's toward venture-backed startups building commercial platforms on top of synthetic DNA supply chains.